These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36250458)

  • 1. The current therapeutic approach for anaemia after kidney transplant.
    Nissaisorakarn V; Nissaisorakarn P; Kantachuvesiri S
    Curr Opin Nephrol Hypertens; 2023 Jan; 32(1):35-40. PubMed ID: 36250458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.
    Stoumpos S; Crowe K; Sarafidis P; Barratt J; Bolignano D; Del Vecchio L; Małyszko J; Więcek A; Ortiz A; Cozzolino M
    Nephrol Dial Transplant; 2024 Sep; 39(10):1710-1730. PubMed ID: 38573822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors.
    Yap DYH; McMahon LP; Hao CM; Hu N; Okada H; Suzuki Y; Kim SG; Lim SK; Vareesangthip K; Hung CC; Nangaku M;
    Nephrology (Carlton); 2021 Feb; 26(2):105-118. PubMed ID: 33222343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
    Zhao H; Li P; Zhang HL; Jia L
    Ren Fail; 2023; 45(2):2258986. PubMed ID: 37724564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis.
    Wu M; Zang C; Ma F; Chen B; Liu J; Xu Z
    Clin Exp Nephrol; 2022 Nov; 26(11):1043-1054. PubMed ID: 36006596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
    Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
    Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia inducible factor-prolyl hydroxylase inhibitors in anemic patients with non-dialysis dependent chronic kidney disease: a meta-analysis of randomized clinical trials.
    Mohamed MMG; Oyenuga M; Shaikh S; Oyenuga A; Kheiri B; Nwankwo C
    Int Urol Nephrol; 2023 Jan; 55(1):167-171. PubMed ID: 35852713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?".
    Crugliano G; Serra R; Ielapi N; Battaglia Y; Coppolino G; Bolignano D; Bracale UM; Pisani A; Faga T; Michael A; Provenzano M; Andreucci M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?].
    Ryšavá R
    Vnitr Lek; 2022; 68(7):438-443. PubMed ID: 36402568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?
    Locatelli F; Del Vecchio L
    Nephrol Dial Transplant; 2020 Jun; 35(6):926-932. PubMed ID: 30844045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M; Tanaka T; Nangaku M
    Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.